What are the Symptoms?

Before convincing you to get tested and try the latest genital herpes treatment, it is important that you understand the symptoms so that you are not subjected to the same myths that continue to help perpetuate this disease. Genital herpes is more than a blister; in fact, it is a virus that remains dormant in the spine after each outbreak. Most often, people with herpes get the commonly known sore, but sometimes an outbreak is little more than tingling, redness and maybe some bumps. So, if you think you may have it, get tested and get treatment.

Is Valtrex the Only Medication on the Market?

While Valtrex is certainly one of the latest genital herpes treatments to hit the mainstream, it is not the only medication available. There are a number of treatments available: These include acyclovir, Zovirax famciclovir, Famvir and valacyclovir. However, Valtrex is one of the only drugs currently available that is taken everyday. Because of this, it has a greater success rate when it comes to decreasing the number of recurrences.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

What are the Side Effects?

Unfortunately, even one of the latest genital herpes treatment, is not without side effects. This is because it is a medication and, like any other drug, sometimes reacts adversely in certain body types. With this in mind, be aware that Valtrex is only intended for patients with a healthy immune system, which includes patients with advanced HIV disease. Also, be sure to inform your doctor should you suffer from kidney problems, because it may be necessary to alter your dosage accordingly.

No, there is no cure for herpes. However, with the latest genital herpes treatment, it is now possible to live a life that is outbreak free. Can you imagine? No more embarrassing and painful sores, which means no more time fidgeting in your chair at work or trying to pick out an outfit that is comfortable when nothing truly is? For this kind of freedom, contact your doctor today and ask her about Valtrex.

Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

And at house parties, there are no chicks that become uncontrollably drunk and then attempt to show you how they can “fire dance,” accidentally setting fire to the host’s potted plant/small dog/infant.

Making the e-mail rounds a few weeks ago — and sent to me by more than one high-profile local sex educator — was a snarky list of ways to “enjoy Burning Man at home.” The list included many observations about the experience, like:

The grant has been made to Dr Lara Maxwell, Assistant Professor of Physiological Sciences at the Oklahoma State Center for Veterinary Health Sciences.

“This virus can affect horses of any age, but causes different signs of disease in foals, pregnant mares, and in other adult horses,” said Dr. Maxwell. “Recent outbreaks of EHV-1 at farms and racetracks around the U.S. have caused severe neurological disease in adult, vaccinated horses. Therefore, current vaccines don’t seem to fully protect these horses from the devastating affects of EHV-1.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Dr. Maxwell will be collaborating with various researchers from the Veterinary Center including Drs. Jerry Ritchey, pathologist, Richard Eberle, virologist, and Charles MacAllister, head of Veterinary Clinical Sciences. The CVHS will also team up with colleagues Drs. Brad Bentz, Hagyard Equine Medical Institute, and George Allen, University of Kentucky.

The study will revolve around the testing of an antiviral drug called valacyclovir. Laboratory and live animal data suggest that this drug will be effective if given in the same doses that Maxwell’s team will be administering.

“We will test the drug to see whether it protects horses from EHV-1,” says Dr. Maxwell. “This is a two year study, but we hope to have preliminary results by the 2008 meeting of the American College of Veterinary Internal Medicine. If the drug is effective, this project will have far reaching consequences for horse owners and the horse industry.”

The Oklahoma State Center for Veterinary Health Sciences is one of 28 veterinary colleges in the United States and is fully accredited by the Council on Education of the American Veterinary Medical Association.

The researchers evaluated acyclovir, valacyclovir, and famciclovir, sold under the trade names Zovirax, Valtrex and Famvir, respectively, in a “meta-analysis,” a review strategy in which the results of several published trials are analyzed to obtain information from a larger total number of patients, which provides the ability to draw more statistically significant conclusions.

Although the use of these drugs to prevent herpes outbreaks began in the early 1980s, the present study is the first meta-analysis to examine their effectiveness compared with placebo, note Dr. Benedicte Lebrun-Vignes, from Hopital Pitie-Salpetriere in Paris, and colleagues in the Journal of the American Academy of Dermatology.

Their review included 14 clinical trials with a total of 6,158 patients with sound immune systems and who were not pregnant. (The drugs should never be taken during pregnancy because they can cause birth defects.)

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

The investigators found that patients who were given one of the three drugs were 47-percent less likely to experience a genital herpes recurrence than those given placebo, the report indicates.

The three agents tested were generally comparable in efficacy. The best regimens for preventing a recurrence were acyclovir 400 mg, valacyclovir 250 mg, or famciclovir 250 mg — all given twice daily — or valacyclovir 500 mg given once daily.

Lebrun-Vignes and associates conclude that all three drugs are suitable treatments for preventing genital herpes outbreaks. However, the authors emphasize the importance of monitoring patients for the possible emergence of drug resistance in patients who do not respond to the standard regimens.

A collaborative group of scientists from the London School of Hygiene and Tropical Medicine (UK), African Medical and Research Foundation (Tanzania) and National Institute for Medical Research (Tanzania), in collaboration with INSERM Unit 743 in Paris and the Institute of Tropical Medicine Antwerp, carried out the trial which was the first anywhere in the world to measure the effects of herpes treatment on HIV acquisition, as well as the long-term effects on the infectivity of people with HIV infection.

Although the results for HIV-positive women taking part in the trial were promising, the findings in HIV-negative women were unclear and more data from larger trials will be needed to establish whether long-term herpes treatment can protect individuals against HIV infection.

1,305 women were recruited in small towns and roadside settlements near Mwanza in North-Western Tanzania, and asked to take the anti-herpes drug acyclovir, or a placebo, twice daily. They were followed for up to 30 months to examine the effects on the incidence of HIV infection in 821 women who were initially HIV-negative, or on markers of HIV infectivity in 484 women who were HIV-positive. In the HIV-positive group, the proportion with HIV detected in their genital secretions after six months and twelve months was 20-25% lower in those taking acyclovir.

The research followed on from observational studies showing that HSV2 infection was associated with around a three-fold higher risk of HIV acquisition 1. HSV2 is a lifelong incurable viral infection, but can be effectively controlled using acyclovir or similar drug treatments. This suggests that controlling herpes might be an effective indirect method of protecting against HIV infection, but trials were needed to test whether this approach works in practice.

HSV2 infection also seems to increase the infectivity of HIV-positive individuals by disrupting the genital mucosa and increasing the levels of HIV in the genital tract. Recent trials in Africa and elsewhere have shown that short-term herpes treatment for up to 3 months successfully reduced genital HIV levels 2, 3 , but further research was needed to measure long-term effects.

Disappointingly, among HIV-negative women there was no overall effect of herpes treatment on the acquisition of HIV, with similar rates seen in both treatment groups. However, there was some evidence that the effect varied according to adherence with treatment. Among women who took at least 90% of their prescribed doses, the HIV rate was 42% lower in those taking acyclovir, but numbers of infections in this subgroup were small, and the difference may have been a chance finding.

Lead author Dr Deborah Watson-Jones, of LSHTM and AMREF, explains: ‘Persuading women to take acyclovir twice a day for two years or more, when they are basically healthy, is obviously difficult although 70% of women did manage to take at least three-quarters of their tablets. However, despite intensive counselling, we were unable in this long-term trial to maintain the very high levels of treatment adherence of over 90% reported in the shorter trials. This may explain why there was no overall effect on HIV acquisition. However our finding of a protective effect in women with the best adherence, even though not statistically significant, leaves us with hope that this could still be an effective strategy in populations where high adherence can be achieved. We need to wait for data from a larger US-funded trial next year to find out whether this approach works as an HIV prevention tool’.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Whatever the results in HIV-negative women, the trial in Tanzania adds to the growing evidence that herpes treatment of HIV-positive individuals reduces their infectivity to sexual partners. The new data suggest that this effect extends for at least 6 to 12 months, and further analyses are now being carried out on specimens taken after 24 months. Data on plasma viral load will also be analysed to see whether there is any evidence that herpes treatment reduces HIV viral replication, as suggested by the results of the shorter-term trials.

Work will continue on the role of herpes control as an indirect preventive measure against HIV. ‘We need every tool we can find to fight the HIV epidemic in Africa’, comments Professor Richard Hayes, a senior investigator on the project. ‘Safer sexual behaviour is of central importance, but we also need to look at ways of cutting the risk of transmission when sexual exposure occurs. We know that male circumcision is one approach and herpes control may be another. We must also press ahead with work to develop effective vaginal microbicides and vaccines’.

‘One thing that this study makes clear is that maintaining adherence to acyclovir over a long period is challenging’, adds Deborah Watson-Jones. ‘An effective HSV2 vaccine would obviously be a more practical way of controlling this virus, and the development of a vaccine needs to be given a higher priority’.

In 2006, an estimated 4.3 million people were newly infected with HIV, of which more than two-thirds lived in sub-Saharan Africa. This high rate of new infections emphasises the need to expand the implementation of proven prevention methods, at the same time as identifying new approaches to prevention.

1. Herpes simplex virus type-2 (HSV2) is the most common sexually transmitted infection and is the main cause of genital herpes. In some parts of sub-Saharan Africa, 70% of women are infected with HSV2 before reaching 30 years of age. HSV2 is an incurable lifelong infection which is asymptomatic for much of the time but causes occasional episodes of genital ulcers and blisters. Genital ulcers are known to be an important risk factor for HIV infection. Even when there are no symptoms, asymptomatic genital excretion of HSV2 may occur, and there is evidence that this also increases the excretion of HIV, thus enhancing the infectivity of HIV-infected individuals.
2. The herpes virus can be targeted by specific antiviral drugs such as acyclovir, valacyclovir or famciclovir. ‘Herpes suppressive therapy’, where one of these drugs is taken daily over a prolonged period, is known to be effective in reducing HSV2 expression and cutting the frequency and severity of clinical episodes of herpes. Acyclovir is a relatively affordable medication, with few side effects and to which the herpes virus rarely becomes resistant. However, its effectiveness in reducing the rate of HIV infection has not been directly tested prior to this trial.
3. In 2001, an international workshop organised by WHO, UNAIDS and LSHTM called for randomised controlled trials of HSV2 therapy to definitively establish a causal relationship between HSV2 and HIV infectivity and acquisition 4 . The first such trials to be reported looked at the effects of short-term herpes treatment (up to 3 months) in HIV-infected individuals in Burkina Faso, South Africa, Peru and Thailand. Taken together, the results showed a clear effect on HIV genital excretion and there was also evidence of an effect on HIV plasma viral load, suggesting that herpes treatment might also reduce the clinical progression of HIV infection. The trial in Tanzania is the first to look at the effects of herpes treatment on HIV acquisition in HIV-negative individuals, as well as long-term effects (up to 30 months) on HIV infectivity in HIV-positive individuals.
4. Two trials of long-term therapy are still in progress. An NIH-funded trial in the US, Peru and Africa (HPTN039) will provide additional data on the effect of herpes suppressive therapy on HIV acquisition and will be completed in 2008. A further multi-centre trial (”Partners in Prevention”), funded by the Bill and Melinda Gates Foundation, is looking at the effect of herpes suppressive therapy in discordant couples (where one partner is HIV-infected and the other is HIV-negative). This trial is scheduled for completion in 2009

Now Mr. Armen is on the move — traveling the world on a quest to persuade regulators to approve the vaccine despite the initial results. His argument: The vaccine worked well in a subgroup of less-sick patients.
[Drug Revolution] DRUG REVOLUTION

See a timeline of important dates in the evolution of the FDA’s standards for approving new medicines.

Yet the U.S. Food and Drug Administration has never approved a drug based on efficacy in a subgroup of patients, defined after a trial. With results in hand, the agency believes, companies theoretically could examine many subgroups before finding one in which their drug appears to work. “It’s like shooting an arrow at a target and after the arrow hits the target, declaring that’s a bull’s eye,” says Robert T. O’Neill, director of biostatistics at a FDA center. “But you don’t look at the arrows on the ground that didn’t make it.”

At root is the question of how much proof is enough — and whether standards should be less rigid to allow quicker approval if medicines have few apparent side effects and would treat deadly diseases in people with limited or no treatment options.

Underlying Mr. Armen’s challenge is the broader frustration between the fast pace of biological breakthroughs in understanding cancer and the relative trickle of novel medicines coming to market to treat it. Critics argue that standards of proof should be relaxed in some cases. They say traditional ways of assessing efficacy could block or delay treatments that bring incremental benefit but may collectively contain cancer.

“We have to find creative ways of getting cancer drugs to patients even if we end up being wrong a few times,” says David Kessler, dean of the school of medicine at the University of California, San Francisco. He was FDA commissioner during the AIDS epidemic, when he amended the approval process to speed 12 new treatments to market.
[Garo Armen]

FDA officials defend the current approval standards, saying it is better to delay a new drug until there is definitive proof it works. “I don’t think you want the FDA to approve a drug saying there’s a chance this works. I think you need to know the therapy works,” says Robert Temple, director of the office of medical policy at the FDA.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

“If somebody uses a vaccine that doesn’t work, they will be forgoing something else,” Dr. Temple says. While he recognizes that some patients have “no options left,” he says the best route for them is to appeal to the FDA and to drug manufacturers for permission to use experimental medicines.

For years, companies have been hesitant to publicly tangle with the FDA, but some are now openly challenging its standards. Pharmacyclics Inc., a California biotech firm, refiled an application in April for approval of a cancer drug, despite the agency’s refusal to review it in February. Cell Therapeutics Inc., a Seattle biotech firm, argues its lung-cancer drug is being delayed by the FDA’s insistence it conduct another trial. Prostate-cancer patients and shareholders have protested the FDA’s refusal in May to approve a cancer vaccine from Dendreon Corp., another Seattle biotech firm, recently buying a half-page ad in the Washington Post, entitled, “Dysfunction at the FDA.”

“When we’re near death, and when there’s little in the medicine cabinet, don’t send these companies back to do another trial,” says Laurie Fenton Ambrose, president of the Washington, D.C.-based Lung Cancer Alliance. She says many lung-cancer patients “would be willing to take greater risk that a treatment doesn’t work.”

The FDA says it can’t comment on specific companies’ data. In 2004, the agency announced a plan to develop ways to approve drugs more quickly. It has held hearings and launched studies, but has yet to adopt significant new guidelines. Meantime, the FDA has been on the defensive on a different front, caught in the cross hairs of patient lawsuits against drug companies whose approved medicines — most notably the painkiller Vioxx — turned out to have serious side effects in rare cases.

Mr. Armen’s journey into drug development began when he was manager of a small health-care investment fund in 1993. Mr. Armen had been obsessed with cancer research since losing his mother to breast cancer soon after emigrating from Turkey 20 years earlier. The two shared a one-room Brooklyn apartment where Mr. Armen administered her morphine shots until she died.

A young researcher from Mount Sinai School of Medicine showed up in Mr. Armen’s office, pitching his research as the basis for a cancer vaccine. Unlike traditional vaccines that prepare the immune system to head off a disease, cancer vaccines aim to induce the body to fight a disease already attacking the body.

Iloilo news site The News Today reported Wednesday that the unlicensed workers are familiar faces to police but continue to prowl the city streets at night.

The report said some 17 of the sex workers are now subject of concern of a local task force, repeatedly flunking the required smearing tests.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

A male complainant guided Task Force agents to the pickup joint where he got the commercial sex worker for a night of promised “fun and excitement.”

Within days, the male customer began to have a mouth infection later diagnosed as herpes.

Task Force chairwoman Mayette Geremias warned the public anew particularly men who frequent the pickup spots to make sure that they are dealing with registered commercial sex workers.

She said the registered ones are card-bearing workers who have government go-signal for a clean bill of health or at least clean of any STD. - GMANews.TV

The ‘Since you’ve been gone” singer insists that she doesn’t like smooching because it’s too “personal” and she’s always worried about what she might catch from potential suitors.

She said in an interview with Blender magazine: “I have major trust issues. I don’t make out with people. That’s a waste of my kisses and my time. And it’s so personal - it’s, like, my face. Plus I’m afraid of mouth herpes!”

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Kelly previously dated US rocker Graham Colton, who she met when Graham’s group, the Graham Colton Band, were the opening act on her ‘Behind These Hazel Eyes Tour’, in 2005.

They split in February 2006 after dating for around seven months due to conflicting work schedules.

Cases of genital herpes rose 9 per cent last year, faster than any other sexual disease. Among teenage girls aged 16 to 19 the rise was even greater, at 16 per cent.

Genital herpes is caused by a virus and is incurable. The virus remains in the body for life and sufferers experience repeated recurrences, which can be severe. The increase pushed total cases of sexually transmitted infections up a further 2 per cent last year to 376,508. Britain has been in the grip of a 10-year epidemic that has seen infections rise by 63 per cent - almost 150,000 extra cases.

Casual sex, an increase in “risky behaviour” and a perception that the diseases are trivial has fuelled the rise. But public health experts said yesterday that there were signs the rise was slowing. Waiting lists for treatment at sexual- health clinics had fallen and there was evidence messages about safe sex were starting to get through.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Professor Pat Troop, the chief executive of the Health Protection Agency, which published the figures yesterday, said: “We have to tackle all the risky behaviours in a society where images involving alcohol, tobacco and sex bombard young people and don’t make it easy for them. If you look at a lot of TV programmes, there is a lot of sexual behaviour and not a lot of thinking about safe sex. You don’t see people in films pulling on a condom.”

The explosion of infections over the past 10 years had been “very worrying” but there were now some “encouraging trends”, with cases of gonorrhoea down for the third year running. “It is still very early and there is no room for complacency. The picture for young people and gay men remains particularly worrying,” Professor Troop said.

Gwenda Hughes, the head of sexually transmitted infections at the agency, said that herpes and gonorrhoea affected different groups, which explained why one could rise while the other fell. Gonorrhoea - down from 25,000 cases in 2003 to 19,000 last year - was concentrated in urban populations among gay men and black ethnic populations, who could be targeted with awareness campaigns. Genital herpes - up from more than 19,000 to almost 22,000 in the same period - was distributed more widely, affecting rural communities as well, and was harder to tackle.

“If you can control gonorrhoea in the core group, you can have a major impact on the infection rate. That is harder to do for genital herpes,” Ms Hughes said.

Genito-urinary clinics were under increasing pressure from the increased workload, up 6 per cent overall last year, but had cut waiting lists. Latest figures showed 85 per cent of patients were seen within 48 hours, according to the Department of Health, compared with less than 40 per cent in 2004.

Here’s the exciting details on how Australian scientists are going to protect the koala population from STD’s.

Professor Peter Timms, from QUT’s Institute of Health and Biomedical Innovation, said chlamydia was a major threat to the continued survival of koalas with almost all populations affected by the disease.

“The trial is planned to begin before the end of the year and will test the vaccine’s ability to induce a good immune response in the koala against chlamydia,” he said.

“Assuming that this first trial is successful, then future trials can determine if this immune response is able to protect the koalas against chlamydial disease.

“We’ve been able to develop the vaccine for koalas as a result of our studies on the development of human chlamydial vaccines done in the mouse model. We have identified several novel vaccine proteins that we hope will protect koalas as well.”

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Professor Timms said chlamydia in koalas was a significant cause of infertility, urinary tract infections, and inflammation in the lining of the eye that often led to blindness.

“The numbers of koalas with chlamydia seems to be increasing,” he said.

“As much as 40-50 per cent of koalas coming into care in both Queensland and NSW are showing clinical signs of the disease and it seems to be getting worse.”

-source-

Maybe if Koalas didn’t have so much group sex like the above picture demonstrates they wouldn’t be in this predicament to begin with. Perhaps the Australian government should call George Bush and ask about his super successful Abstinence only education that has been sweeping the U.S.